EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

miR-130b-3p/NR3C2: a novel prognostic biomarker and drug screening target for clear cell renal cell carcinoma

Guanfeng Luo, Wenbin Yu, Fangxin Chen, Minyu Liu, Dexian Li, Jie Zhou, Jun Liu, Hiu Yee Kwan, Liming Fan, Yanting You, Xiaoshan Zhao, Xiaomin Sun

Frontiers in Oncology · 20.11.2026 · 16

DOI: 10.3389/fonc.2026.1976138 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 20.11.2026. Verfasst von Guanfeng Luo und 11 weiteren Autor:innen. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clear cell renal cell carcinoma (ccRCC) represents a malignancy with pronounced heterogeneity, and dependable biomarkers for predicting prognosis and therapeutic response are still scarce. MicroRNAs (miRNAs) contribute importantly to the advancement of tumors. Nevertheless, the specific function of miR-130b-3p in ccRCC is still unclear.

Methods

Using the TCGA-KIRC cohort, we carried out differential expression profiling and built a weighted gene co-expression network. To systematically identify miRNAs and their corresponding target genes, we developed an integrative analytical framework incorporating machine learning methodologies. Prognostic models were constructed and evaluated, while single-cell transcriptomic analysis and in vitro experiments were used to characterize the cellular and functional relevance of the selected markers. Potential therapeutic agents were explored through virtual screening and molecular docking.

Results

Herein, we employed both weighted gene co-expression network analysis and differential expression analysis to pinpoint miR-130b-3p and the immune-related gene NR3C2. Subsequently, we established a prognostic model incorporating miR-130b-3p and NR3C2 as core components, which showed prognostic discrimination in the analyzed cohorts. Risk stratification revealed distinct molecular characteristics, immune microenvironment profiles, and computationally inferred immune- evasion characteristics. Moreover, single-cell transcriptomic analysis characterized the cellular distribution of NR3C2, while in vitro experiments showed that miR-130b-3p inhibition increased NR3C2 mRNA expression and suppressed ccRCC cell proliferation, migration, and invasion. Finally, five putative docking-derived candidate compounds—digoxin, venetoclax, amphotericin B, ledipasvir, and natacyn—were identified through virtual screening and molecular docking.

Conclusion

The putative miR-130b-3p–NR3C2 relationship may have potential value for prognostic stratification and characterization of immune-related features in ccRCC. Structure-based virtual screening identified five FDA-approved compounds—digoxin, venetoclax, amphotericin B, ledipasvir, and natacyn—as putative binders of the modeled pre-miR-130b structure. These findings provide a basis for further experimental and clinical evaluation of miR-130b-3p and NR3C2 in ccRCC.

Zitieren

APA

Luo, G., Yu, W., Chen, F., Liu, M., Li, D., Zhou, J., Liu, J., Kwan, H. Y., Fan, L., You, Y., Zhao, X., & Sun, X. (2026). miR-130b-3p/NR3C2: a novel prognostic biomarker and drug screening target for clear cell renal cell carcinoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1976138

Vancouver

Luo G, Yu W, Chen F, Liu M, Li D, Zhou J, et al. miR-130b-3p/NR3C2: a novel prognostic biomarker and drug screening target for clear cell renal cell carcinoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1976138

BibTeX
@article{Luo2026,
  author = {Luo, Guanfeng and Yu, Wenbin and Chen, Fangxin and Liu, Minyu and Li, Dexian and Zhou, Jie and Liu, Jun and Kwan, Hiu Yee and Fan, Liming and You, Yanting and Zhao, Xiaoshan and Sun, Xiaomin},
  title = {miR-130b-3p/NR3C2: a novel prognostic biomarker and drug screening target for clear cell renal cell carcinoma},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1976138}
}
Kostenlos starten →